News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
GlaxoSmithKline To Take $2.4 Billion Charge To Cover Avandia Cases, Other Legal Woes
July 26, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NPR -- Even for a flush drugmaker like GlaxoSmithKline, $2.4 billion dollars is a lot of money to wipe off the books in a single quarter.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Europe
GlaxoSmithKline
MORE ON THIS TOPIC
IN PARTNERSHIP WITH IQVIA
AI Is Taking Over Drug Safety Monitoring–But There’s One Thing It Can’t Replace
July 17, 2025
·
1 min read
·
Lori Ellis
Layoffs
HHS Begins Formally Laying Off Employees
July 15, 2025
·
2 min read
·
Tristan Manalac
Policy
FDA Commissioner Marty Makary Proposes Lowering Industry User Fees
July 15, 2025
·
2 min read
·
Tristan Manalac
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
·
6 min read
·
Lori Ellis
